This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Small correction to my own earlier position on molecular mass of semaglutide. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.
The question underneath molecular mass of semaglutide is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
Narrowing post #30, because the general version has more than one answer.
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
I would be interested in a counterexample if anyone has one.
Everything in post #32 holds. The case it does not cover is the one I have.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
That holds for the case as described. Change the assumptions and it may not.
Post #33 is the version of this I will quote in future. One addition.
The oral formulation is a genuinely different pharmaceutical problem from the injectable and shares only the active molecule. Absorption enhancers, fasting requirements and a very different bioavailability mean dose numbers do not translate between the two at all.
That has held every time I have looked, which is not the same as always.
The confident answers on molecular mass of semaglutide and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
Nausea is dose-related and adaptation-related, and both are true at once. The pattern most people describe is a return of symptoms at each escalation followed by adaptation, rather than a single course of adaptation at the start.
Quietly grateful for the plain phrasing. Not every thread gets that.
This follows post #37 rather than contradicting it.
The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.
The right answer here may simply be that it has not been measured.
Worth separating two things that post #36 runs together.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
The short answer was in the first line; everything after is the working.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
Counterpoint on molecular mass of semaglutide, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Taking post #41 at face value and following it one step further.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
Posted with less confidence than the sentence structure implies.
Answering the question post #41 raises rather than the one it answers.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
Somebody will have a better source than mine, and I hope they post it.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
It is worth checking rather than assuming, which costs nothing.
Molecular mass of semaglutide came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
Post #49 is right about the mechanism and I think understates the practical bit.
I read the earlier replies on molecular mass of semaglutide twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
Right, and stated more narrowly than I would have dared to state it.
Coming back to post #50, because the follow-up matters more than the original answer.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.
That is what the documentation says. What happens in practice is usually close.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
This is where my knowledge stops and I would rather mark the edge than blur it.
Post #52 answers the question as asked. The question underneath it is different.
Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.
The strongest argument against my own position on molecular mass of semaglutide, stated as well as I can state it, since nobody else has yet.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Two sources, same conclusion, and I could not rule out that one copied the other.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
It cost nothing to check and would have cost something not to.
Molecular mass of semaglutide is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
Helpful, and easy to find again, which is half of what a good reply is.